XML 35 R11.htm IDEA: XBRL DOCUMENT

INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	12 Months Ended
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET The Company incurred intellectual property litigation expenses, including settlements and external legal costs, of $15.8 million, $20.6 million and $405.4 million during 2022, 2021 and 2020, respectively. On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries ("Abbott") to, among other things, settle all outstanding patent disputes between the companies (the “Settlement Agreement”) in cases related to transcatheter mitral and tricuspid repair products. The Settlement Agreement resulted in the Company recording an estimated $367.9 million pre-tax charge and related liability in June 2020 related to past damages. In addition, the Company will incur royalty expenses through May 2024 totaling an estimated $70 million. The Company made a one-time $100.0 million payment to Abbott in July 2020, and is making quarterly payments in subsequent years. As of December 31, 2022, $53.3 million was accrued in "Accrued and other liabilities" and $143.0 million was accrued in "Litigation settlement accrual" on the consolidated balance sheet.